Celcuity Reports Preliminary Data from Phase 1b Trial of Gedatolisib plus Ibrance and Endocrine Therapy for Patients with ER+/HER2- Metastatic Breast Cancer and Provides Corporate Update

By Business Wire3 days ago


Preliminary Phase 1b Data

-53 of the 88 evaluable patients (60%) had an objective response -

-Gedatolisib showed a potentially differentiated safety and tolerability profile -

Corporate Update

- Entered $25 million debt financing agreement with Innovatus Capital Partners -

Continue read on benzinga.com